===
EQS-News: BRAIN Biotech AG / Key word(s): Alliance/Sustainability
Beverages made from vine leaves: Sustainable drinking pleasure based on agricultural side streams
2024-03-14 / 09:00 CET/CEST
The issuer is solely responsible for the content of this announcement.
Beverages made from vine leaves: Sustainable drinking pleasure based on agricultural side streams
. BRAIN Biotech, Tropical Viticulture Consultants, Zukunftsweine and Provadis Hochschule jointly develop
sustainable, non-alcoholic beverages from agricultural side streams
. Consortium reaps benefits of new grape varieties adapted to climate change
. Life cycle analysis and technical-economic analysis accompany different process variants
Zwingenberg, Mainz, Frankfurt, Friedrichsdorf (Germany), 14 March 2024 - At the beginning of the year, a
multidisciplinary German consortium of biotechnologists, oenologists, winemakers and sustainability experts started
work on an innovation project funded by the German Federal Ministry of Education and Research (BMBF): The "SusBev" (for
"Sustainable Beverages") project is a sub-project of the "Bioeconomy Innovation Space in Metropolitan Regions"
(BioBall) - and thus one of four initiatives in the focus of the BMBF's National Research Strategy Bioeconomy 2030.
The aim of the "SusBev" project is to use and ferment agricultural residues and side streams from viticulture and other
regional agricultural processes to produce healthy and tasty beverages and food.
Harnessing flavors from vine leaves
In their first project, the researchers are working with wine experts to use the leaves of new grape varieties adapted
to climate change to make wine-like drinks. The vine leaves and shoots of these varieties, which have not yet been used
as a raw material, are suitable because they have an attractive, varietal flavor (like the berries from which wine is
made). In addition, their resistance to fungal attack means that the plants require less pesticide treatment, making
them safe for consumption.
BRAIN Biotech AG, Tropical Viticulture Consultants (TVC), Zukunftsweine GmbH (ZW) and Provadis Hochschule are
participating in the SusBev project. In particular, TVC provides expertise in the selection, harvesting and processing
of suitable side streams. BRAIN Biotech is responsible for the selection and optimization of suitable microorganisms
(starter cultures) as well as the basic establishment of the bioprocess on a laboratory scale. ZW and TVC transfer the
laboratory results and test them in the winery. ZW will also support product development from a market perspective and
develop a product brand profile. Provadis University of Applied Sciences will conduct a life cycle analysis to assess
the environmental impact and a technical and economic analysis for the different process variants.
BMBF is funding the project "Innovationsraum: BioBall - SusBev - nachhaltige Getränke und Lebensmittel auf Basis
landwirtschaftlicher Seitenströme" (funding code: 031B1476A) on a pro rata basis for the benefit of the funding
recipients over a period of two years. The grantees will invest their own funds in the amount of the grant to
successfully achieve the project objectives - starter cultures, production processes and prototypes.
+++
About BRAIN Biotech
BRAIN Biotech AG is a leading European supplier of bio-based products and solutions such as enzymes and proteins,
microbial production strains, natural compounds and biotechnological solutions for more sustainable industrial
processes. The company focuses on the fields of nutrition, health and environment.
BRAIN Biotech AG is the parent company of the international BRAIN Biotech Group. The Group's business activities are
divided into three segments: The BioProducts segment comprises the product business with specialty enzymes and other
proteins, for which the Group operates fermentation facilities in the United Kingdom and production facilities in
continental Europe and the United States. The BioScience segment offers research-intensive custom solutions based on
enzyme technology, strain development, bioprocess development and natural product screening. The BioIncubator segment
conducts its own R&D projects or those initiated with partners with high value-added potential. A particularly
promising incubator project is the development of the Company's own CRISPR-based gene editing technology platform,
which is currently being established and expanded by Akribion Genomics (in foundation planning).
Through its own R&D activities, BRAIN Biotech Group is continuously expanding its product portfolio in the field of
specialty enzymes and small molecules. The latter are the starting point for screenings, e.g. for novel drug candidates
for pharmaceutical applications.
BRAIN Biotech AG has been listed on the Prime Standard of the Frankfurt Stock Exchange since February 9, 2016 (ticker
symbol: BNN; securities identification number: ISIN DE0005203947 / WKN 520394). The company employs approximately 330
people and generated revenues of EUR 55.3 million in the fiscal year 2022/23.
For more information, please visit: https://www.brain-biotech.com, LinkedIn, Threads and YouTube.

Contact Media
Dr. Stephanie Konle
PR & Corporate Communications
Phone: +49 6251 9331-70
Email: stk@brain-biotech.com

Contact Investor Relations
Martina Schuster
Investor Relations
Phone: +49 6251 9331-69
Email: ms@brain-biotech.com

Disclaimer
This press release contains forward-looking statements. These statements reflect the current views, expectations, and
assumptions of the management of BRAIN Biotech AG, and are based on information currently available to the management.
Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as
uncertainties that could cause actual results, performance or events to differ materially from those expressed or
implied in such statements. Numerous factors exist that could influence the future performance of and future
developments at BRAIN Biotech AG and the BRAIN Biotech Group. Such factors include, but are not limited to, changes in
the general economic and competitive environment, risks associated with capital markets, currency exchange rate
fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and
regulations, as well as other factors.
BRAIN Biotech AG does not undertake any obligation to update or revise any forward-looking statements.

2024-03-14 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.eqs-news.com  
Language:     English 
Company:      BRAIN Biotech AG 

Darmstädter Straße 34-36
64673 Zwingenberg
Germany

Phone:        +49 (0) 62 51 / 9331-0 
Fax:          +49 (0) 62 51 / 9331-11 
E-mail:       ir@brain-biotech.com 
Internet:     www.brain-biotech.com 
ISIN:         DE0005203947 
WKN:          520394 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 

Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1858225

End of News EQS News Service
===
1858225 2024-03-14 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1858225&application_name=news

END) Dow Jones Newswires

March 14, 2024 04:00 ET (08:00 GMT)